Aevi Genomic Medicine, Inc.
(NASDAQ : GNMX)

( )
GNMX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -0.73%158.710.0%$1286.08m
AMGNAmgen, Inc. 0.00%255.131.3%$694.68m
NVAXNovavax, Inc. 0.95%204.0080.0%$561.76m
SNSSSunesis Pharmaceuticals, Inc. 0.00%8.030.7%$561.33m
ILMNIllumina, Inc. 0.00%401.963.5%$517.94m
GILDGilead Sciences, Inc. 0.00%65.771.0%$463.29m
REGNRegeneron Pharmaceuticals, Inc. 0.00%494.642.7%$449.68m
VRTXVertex Pharmaceuticals, Inc. 0.00%221.101.9%$383.88m
ALXNAlexion Pharmaceuticals, Inc. 0.00%157.542.0%$298.86m
BNTXBioNTech SE -0.63%139.840.0%$264.71m
BIIBBiogen, Inc. 0.00%270.451.7%$264.46m
EXASEXACT Sciences Corp. 0.00%130.5218.4%$192.20m
NBIXNeurocrine Biosciences, Inc. 0.00%95.004.9%$177.73m
CRSPCRISPR Therapeutics AG -0.13%123.690.6%$174.27m
SGENSeagen Inc. 0.00%149.645.8%$153.69m

Company Profile

Aevi Genomic Medicine focuses on translating genetic discoveries into novel therapies. It is dedicated to unlocking the potential of genomic medicine to translate genetic discoveries into novel therapies. Driven by a commitment to patients with pediatric onset life-altering diseases, the company's research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics at The Children's Hospital of Philadelphia.